Halozyme Therapeutics (HALO) revenue

Revenue · fiscal 2025
$1.40B

Halozyme Therapeutics (HALO) reported revenue of $1.40B in fiscal 2025 (the year ended December 31, 2025). That is 37.6% higher than the $1.02B of fiscal 2024. Figures as of 18 Nov 2026, 10:45 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$1.40B
Change on fiscal 2024
+37.6%
Growth, 5 years
+39.2% a year
Growth, 10 years
+26.3% a year
Highest on record
$1.40Bfiscal 2025
Lowest on record
$13.62Mfiscal 2010
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Halozyme Therapeutics revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 39.2% a year; over ten years the rate was 26.3% a year. Across the 17 fiscal years on record (2009–2025), the highest was $1.40B in fiscal 2025 and the lowest $13.62M in fiscal 2010.

History · 17 fiscal years

Revenue by fiscal year

Halozyme Therapeutics revenue, year by year

Halozyme Therapeutics (HALO) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$1.40B 37.6% up
2024$1.02B 22.4% up
2023$829.25M 25.6% up
2022$660.12M 48.9% up
2021$443.31M 65.7% up
2020$267.59M 36.5% up
2019$195.99M 29.1% up
2018$151.86M 52.0% down
2017$316.61M 115.8% up
2016$146.69M 8.6% up
2015$135.06M 79.3% up
2014$75.33M 37.5% up
2013$54.80M 29.5% up
2012$42.33M 24.5% down
2011$56.09M 311.7% up
2010$13.62M 0.3% down
2009$13.67M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Halozyme Therapeutics and comparable companies
CompanyRevenueFiscal year
Fresenius Medical Care FMS€19.63B2025
Kymera Therapeutics KYMR$39.21M2025
DaVita DVA$13.64B2025
Halozyme Therapeutics HALO$1.40B2025
Universal Health Services UHS$17.36B2025
Repligen RGEN$738.26M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on HALO

Halozyme Therapeutics, figure by figure

Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value

Halozyme Therapeutics revenue: questions and answers

What is Halozyme Therapeutics's revenue?

Halozyme Therapeutics (HALO) reported revenue of $1.40B in fiscal 2025 (the year ended December 31, 2025). That is 37.6% higher than the $1.02B of fiscal 2024.

What is the growth rate of Halozyme Therapeutics's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 39.2% a year; over ten years the rate was 26.3% a year.

What are the highest and lowest revenue figures on record for Halozyme Therapeutics?

Across the 17 fiscal years on record (2009–2025), the highest was $1.40B in fiscal 2025 and the lowest $13.62M in fiscal 2010.

How is Halozyme Therapeutics's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Halozyme Therapeutics it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Halozyme Therapeutics (HALO) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/HALO/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.